The purpose is to conduct a dietary intervention study in which human participants will consume beverages sweetened with erythritol or aspartame, each for 2 weeks, in a randomized crossover design
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
P-selectin, a platelet surface marker, assessed as median fluorescence intensity
Timeframe: 6 weeks
P-selectin, a platelet surface marker, assessed as percentage of P-selectin positive cells
Timeframe: 6 weeks
PAC-1 (GPIIb/IIIa complex), a platelet surface marker, assessed as median fluorescence intensity
Timeframe: 6 weeks
PAC-1 (GPIIb/IIIa complex), a platelet surface marker, assessed as percentage of PAC-1 positive cells
Timeframe: 6 weeks
Annexin V, a platelet surface marker, assessed as median fluorescence intensity
Timeframe: 6 weeks
Annexin V, a platelet surface marker, assessed as percentage of annexin V positive cells
Timeframe: 6 weeks
Platelet reactivity to physiologic agonist, assessed as change in median fluorescence intensity
Timeframe: 6 weeks
Platelet aggregation in response to physiologic agonist, assessed as aggregation/min
Timeframe: 6 weeks
Platelet aggregation in response to physiologic agonist, assessed as percent of maximum aggregation
Timeframe: 6 weeks
Platelet-leukocyte interaction, assessed as platelet/leukocyte aggregate size by fluorescence mean intensity
Timeframe: 6 weeks